Clinical comparsion between paclitaxel combined with capecitabine and fluorouracil in the first-line treatment of advanced gastric cancer

Objective: To observe the effects and adverse reactions of paclitaxel combined with capecitabine or fluorouracil in the treatment of advanced gastric cancer. Methods: Seven-six patients with advanced gastric cancer were randomly divided into the observation group and control group(38 cases each group). The observation group were treated with paclitaxel combined with capecitabine, the mixture of 150 mg/m² of paclitaxel(at day 1 and 8) and 0.9% sodium chloride injection was intravenously injected for 3 h, and the 750 mg/m² of capecitabine was used by oral 2 times daily from day 1 to 14. The control group were treated with paclitaxel combined with fluorouracil, the usage of paclitaxel was the same as the observation group, the 500 mg/m² of 5-fluorouracil was used once a day for 5 d after 2 h of the 130 mg/m² of leucovorin calcium intravenous dripping. Results: The effective rates of the observation group and control group were 52.63%, and 50.00%, respectively, the difference of which was not statistically significant(P>0.05). The median progression-free time and median survival time in observation group and control group were 6.7 months & 11.8 months and 6.2 months & 11.3 months, respectively. The difference of 1-year survival rate between two groups was not statistically significant(P>0.05). The incidence of hand-foot syndrome in observation group was significantly higher than that in control group(P<0.01). Conclusions: The effects of paclitaxel combined with capecitabine or fluorouracil in the treatment of advanced gastric cancer are similar, the tolerance of patients is good.